Taiho Pharmaceutical Company Limited

Msd K.k.

Canon Kabushiki Kaisha

Banyu Pharmaceutical Co. Ltd

Masanori Asai

Takahiro Asai

Shigeo Okajima

Kazuhisa Minamiguchi

Kazuhiro Funatani

Hiroyuki Seki

Yasutaka Yagi

Shuji Saito

Tetsuichiro Fujimoto

Shinichi Aoki

Hiroyoshi Yamanaka

Akio Ohno

Suguru Dohi

Norikazu Otake

Makoto Ishikawa

Yoshio Ogino

Tomoharu Iino

Takuya Suga

Teruyuki Nishimura

Hirobumi Takahashi

Norikazu Ohtake

Takashi Yoshizumi

Tetsuya Kato

Yufu Sagara

Noriaki Hashimoto

Seiichi Inamura

Yuichi Sugimoto

Hiroshi Miyazoe

To provide a compound having an inhibitory activity for an androgen receptor. A fused pyrimidine compound represented by the following formula (I) or a pharmaceutically acceptable thereof (in the formula, X, Y, Z, R, and Rare as defined in the specification). 

Fused pyrimidine compound or salt thereof

A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof 

Tetrahydropyridopyrimidine compound or salt thereof

An image forming apparatus includes a controller for forming an adjustment toner image in a region corresponding to between a first region corresponding to a preceding sheet and a second region corresponding to a subsequent sheet, wherein the controller selectively executes a first mode for setting as a first length a gap between the adjustment image and a trailing edge of the first region and for setting as a second length a gap between the adjustment toner image and a leading end of the second region, or a second mode for setting as a third length a gap between the adjustment toner image and the trailing edge of the first region and for setting as a fourth length a gap between the adjustment image and the leading end of the second region. The third is shorter than the first, and the fourth length is longer than the first length.

Image forming apparatus utilizing adjustment toner image

A tetrahydropyridopyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition including the tetrahydropyridopyrimidine compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier: 

An image forming apparatus including a cleaning member having a belt cleaning blade and a conductive brush. A value of a charging current that is generated when charging residual toner with the conductive brush is smaller when a color mode is executed compared to that when a monochrome mode is executed.

Image forming apparatus

In an adjustment step, an adjustment purpose toner image is formed on an intermediate transfer belt, and the adjustment purpose toner image is removed from the intermediate transfer belt by a cleaning member contacting the intermediate transfer belt and through an electrostatic cleaning step. This adjustment step is executed in a state where a toner attachment amount on a charging member is switched from a first limit value, which is allowed in the image forming step to a second limit value, which is allowed immediately before executing the adjustment step. This switching is performed by the execution of a toner discharging step, where a power supply changes the state of applying voltage to the charging member from that in the electrostatic cleaning step, so that toner attached to the charging member is transferred to the intermediate transfer belt.

Image forming apparatus with cleaning using cleaning member and charging member

Disclosed are compounds of the following formula and their pharmaceutically-acceptable salts, which have an effect of glucokinase activation and are useful in the field of medicines for treatment for diabetes, obesity, etc. (wherein ring A represents a pyrazolyl group optionally having a lower alkyl group, etc.; ring B represents a heteroaryl group; R represents a lower alkyl group, etc.; Rrepresents a group of a formula: (wherein Rand Reach independently represent a hydrogen atom, etc.; m indicates an integer of from 2 to 6), etc.;Rrepresents a lower alkyl group, etc.; r indicates an integer of from 0 to 3; k indicates an integer of from 0 to 4).

Heteroaryl quinazoline derivatives

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof. 

Oxotetrahydrofuran-2-yl-benzimidazole derivative

Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity.  Rand Reach independently represent a lower alkyl group; Xrepresent a group of a formula (II-1): wherein:Rand Reach independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH), Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

2-pyridinecarboxamide derivative having GK-activating effect

Heteroaryloxy quinazoline derivative

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.

Cycloalkanopyridine derivative

Growing community of inventors

Tsukuba, Japan

Masanori Asai